As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Dr Reddy'S Laboratories Ltd. The largest reported stake is G.V. Prasad's, at 13.58%. One filing is on record since September 18, 2025 (Schedule 13D/A, September 18, 2025).
Sell to companies like Dr Reddy'S Laboratories Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: G.V. Prasad · Sole voting: 0 · Shared voting: 108,813,010 · Sole dispositive: 0 · Shared dispositive: 108,813,010 · SCHEDULE 13D/A, 2025-09-18
- · Reporting person: K. Satish Reddy · Sole voting: 10,107,505 · Shared voting: 103,249,005 · Sole dispositive: 10,107,505 · Shared dispositive: 103,249,005 · SCHEDULE 13D/A, 2025-09-18
- · Reporting person: GVP Family Trust · Sole voting: 96,095,920 · Shared voting: 0 · Sole dispositive: 96,095,920 · Shared dispositive: 0 · SCHEDULE 13D/A, 2025-09-18
- · Reporting person: VSD Family Trust · Sole voting: 75,630,620 · Shared voting: 0 · Sole dispositive: 75,630,620 · Shared dispositive: 0 · SCHEDULE 13D/A, 2025-09-18
- · Reporting person: G. Anuradha · Sole voting: 46,025 · Shared voting: 96,095,920 · Sole dispositive: 46,025 · Shared dispositive: 96,095,920 · SCHEDULE 13D/A, 2025-09-18
Dr Reddy'S Laboratories Ltd has 1 Schedule 13D or 13G filing on record since 2025-09-18. 1 holder's latest filing reports 5% or more of american depositary shares, each representing one equity share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 13.58% | 108,813,010 | SCHEDULE 13D/A, 2025-09-18 | 2025-09-17 |
Holding shares or following this stake? See who's behind Dr Reddy'S Laboratories Ltd and the warning signs.
Free to see. No signup.
Watch Dr Reddy'S Laboratories Ltd
Get an email when Dr Reddy'S Laboratories Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Dr Reddy'S Laboratories Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Dr Reddy'S Laboratories Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dr Reddy'S Laboratories Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| G.V. Prasad | 0 | 108,813,010 | 0 | 108,813,010 | SCHEDULE 13D/A, 2025-09-18 |
| K. Satish Reddy | 10,107,505 | 103,249,005 | 10,107,505 | 103,249,005 | SCHEDULE 13D/A, 2025-09-18 |
| GVP Family Trust | 96,095,920 | 0 | 96,095,920 | 0 | SCHEDULE 13D/A, 2025-09-18 |
| VSD Family Trust | 75,630,620 | 0 | 75,630,620 | 0 | SCHEDULE 13D/A, 2025-09-18 |
| G. Anuradha | 46,025 | 96,095,920 | 46,025 | 96,095,920 | SCHEDULE 13D/A, 2025-09-18 |
| Deepti Reddy | 25,700 | 75,630,620 | 25,700 | 75,630,620 | SCHEDULE 13D/A, 2025-09-18 |
The latest filing identifies Dr Reddy'S Laboratories Ltd by CUSIP 256135203 and gives its principal executive office as 8-2-337, ROAD NO.3 BANJARA HILLS, HYDERABAD (SCHEDULE 13D/A, 2025-09-18).
Source of funds (Item 3)
Item 3 of the Amended Schedule 13D is hereby amended and supplemented as follows: GVP Family Trust. GVP Family Trust directly owns 96,095,920 Post-Split Shares, all of which were transferred to it by Mr. G.V. Prasad for estate planning and family succession purposes on September 17, 2025. The source of funds for such 96,095,920 Post-Split Shares held by GVP Family Trust are as follows: All such 96,095,920 Post-Split Shares were acquired by Mr. G.V.G.V. Prasad, SCHEDULE 13D/A, 2025-09-18
Purpose of Transaction (Item 4)
G.V. Prasad
Item 4 of the Amended Schedule 13D is hereby amended and supplemented as follows: On September 17, 2025, Mr. G.V. Prasad transferred 96,095,920 Post-Split Shares to GVP Family Trust and Mr. K. Satish Reddy transferred 75,630,620 Post-Split Shares to VSD Family Trust. These transfers of shares were done for estate planning purposes, and to implement family succession arrangements and planning for a smooth and streamlined transfer of family assets and businesses.Item 4 of the SCHEDULE 13D/A filed 2025-09-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-18 | G.V. Prasad | 13.58% | SCHEDULE 13D/A |
Tools for this story
Each opens in a new tab, filled in for Dr Reddy'S Laboratories Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.